Core D - Training and Outreach The overall objective of the Training and Outreach Core is to provide an integrated educational and practical mentored research training experience for health sciences professionals interested in pediatric antimicrobial developmental pharmacology. Dr. Best, who leads our T35 Training program in Pediatric Pharmacology, will lead this Core. Dr. Tremoulet, leveraging existing community outreach infrastructure developed for Kawasaki Disease monitoring, will assist her with the outreach objectives of this Core. The broad philosophy of the training program is that training and education can be offered at various levels of background and experience, and tailored to the scholar's interests, so that we can attract a wide range of health science professionals from our institution and from our partner RPDP Centers to participate in all of our Projects and the PM and QP Core activities. General research training programs in the Schools of Pharmacy, Medicine, as well as in the Rady Children's Hospital, and the UCSD Medical Center provide a rich source of health sciences pre- and postdoctoral trainees enthusiastic about establishing careers in clinical pediatric pharmacology. In concert with effective training, the Core will communicate with scientific and lay communities to increase awareness of the important differences in drug metabolism, excretion and actions between pediatrics and adults.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54HD071600-03
Application #
8473258
Study Section
Special Emphasis Panel (ZHD1-DSR-A)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
3
Fiscal Year
2013
Total Cost
$26,285
Indirect Cost
$9,327
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Kumaraswamy, Monika; Do, Carter; Sakoulas, George et al. (2018) Listeria monocytogenes endocarditis: case report, review of the literature, and laboratory evaluation of potential novel antibiotic synergies. Int J Antimicrob Agents 51:468-478
Choe, Donghui; Szubin, Richard; Dahesh, Samira et al. (2018) Genome-scale analysis of Methicillin-resistant Staphylococcus aureus USA300 reveals a tradeoff between pathogenesis and drug resistance. Sci Rep 8:2215
Sakoulas, George; Kumaraswamy, Monika; Kousha, Armin et al. (2017) Interaction of Antibiotics with Innate Host Defense Factors against Salmonella enterica Serotype Newport. mSphere 2:
Sakoulas, George; Rose, Warren; Berti, Andrew et al. (2017) Classical ?-Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii. Antimicrob Agents Chemother 61:
Natale, Stephanie; Bradley, John; Nguyen, William Huy et al. (2017) Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing. Pharmacotherapy 37:361-378
Sakoulas, George; Olson, Joshua; Yim, Juwon et al. (2016) Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother 60:6609-6618
Lin, Leo; Kim, Janie; Chen, Hope et al. (2016) Component Analysis of Multipurpose Contact Lens Solutions To Enhance Activity against Pseudomonas aeruginosa and Staphylococcus aureus. Antimicrob Agents Chemother 60:4259-63
Hollands, Andrew; Corriden, Ross; Gysler, Gabriela et al. (2016) Natural Product Anacardic Acid from Cashew Nut Shells Stimulates Neutrophil Extracellular Trap Production and Bactericidal Activity. J Biol Chem 291:13964-73
Shoji, Kensuke; Bradley, John S; Reed, Michael D et al. (2016) Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent Organisms. Antimicrob Agents Chemother 60:2150-6
Lam, Lisa H; Capparelli, Edmund V; Kurzrock, Razelle (2016) Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib. Cancer Chemother Pharmacol 78:427-32

Showing the most recent 10 out of 71 publications